• A
  • A
  • A

Ute Moll, M.D., Professor

Ute Moll, MD, MS 
Professor
Vice Chair for Experimental Pathology
Basic Sciences Tower, Level 9
Stony Brook Medicine
Stony Brook, NY 11794-8691
Tel: (631) 444-2459
Fax: (631) 444-3424
Email: Ute.Moll@stonybrookmedicine.edu

Clinical Practice:

Dr. Moll currently participates in the autopsy program at Stony Brook University Hospital.

Education:
Institution & Location Degree Year(s) Field of Study
University of Ulm, Germany MS 1980 Biology
University of Ulm, Germany MD 1985 Medicine

Research Summary:

Newsday publication

Positions and Employment:

1986-1989 Resident, Anatomic & Clinical Pathology, Stony Brook University
1989-1990 Postdoctoral Research Fellow, Stony Brook University, lab of Dr. James Quigley
1991-1992 Postdoctoral Research Fellow, Princeton University, lab of Dr. Arnold J. Levine
1992-1997 Assistant Professor, Department of Pathology, Stony Brook University
1997-2001 Associate Professor, Department of Pathology, Stony Brook University
2002-present Full Professor, Department of Pathology, Stony Brook University
2009-present Vice Chair, Research, Department of Pathology Stony Brook University
2012-present Co-Director, Stem Cell Analysis Core, Stony Brook Stem Cell Facility


Other Experience and Professional Memberships (selected):

1988-1989 Chief Resident, Department of Pathology, Stony Brook University
2007-present Guest Professor, Department of Molecular Oncology, University of Göttingen, Germany


Honors (selected):

2006 Baldwin Award for Cancer Research, Stony Brook University
2011 Baldwin Award for Cancer Research, Stony Brook University
2012 Fusion Award, Stony Brook University
2013 Inaugural Excellence in Basic Research Award, School of Medicine, Stony Brook University
2017 Induction as Member, Association of American Physicians  (AAP)
2017 SUNY Central Chancellor's Award for Excellence in Scholarship


Selected publications (of total of 166):

  1. Schulz-Heddergott R, Stark N, Edmunds S, Li J, Conradi L, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM . Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Schulz-Heddergott et al., 2018, Cancer Cell 34, 298–314, August 13, 2018 ª 2018 Elsevier Inc. https://doi.org/10.1016/j.ccell.2018.07.004.

  2. Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M (2017). Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death Differ 24(2):300-316.

  3. Nemajerova A*, Kramer D, et al. Bonn S, Takemaru K-I, Moll UM* and Lizé M* (2016). TAp73 is a central transcriptional regulator of airway multiciliogenesis. Genes & Development, 30(11):1300-12. Featured on Journal Cover. Editorial by Napoli M, Flores ER. Unifying the p73 knockout phenotypes: TAp73 orchestrates. multiciliogenesis. Genes Dev. 2016 Jun 1;30(11):1253-4

  4. Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M (2015). microRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Mol Cell, 59(2):243-57

  5. Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M (2015). MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness- Promoting Chromatin Modifications Independent of p53. Mol Cell, 61(1):68-83.
  6. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M and Moll UM. (2015) Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment.  Nature, 523(7560): 352-6.
  7. Holembowski L, Kramer D, Riedel D, Sordella R, Nemajerova A, Dobbelstein M and Moll UM (2014). TAp73 is essential for germ cell adhesion and maturation in testis. Journal Cell Biology, 204 (7), 1173-1190. Featured in Journal’s Highlights. Featured in  Asian J Androl (2014)16, 799-800.

  8. Yallowitz AR, Alexandrova EM, Talos F, Xu S, Marchenko ND and UM Moll (2014) p63 is a prosurvival factor in the adult mammary gland during post-lactational involution, affecting PI-MECs and ErbB2 tumorigenesis. Cell Death Diff  doi: 10.1038/cdd.2013.199.
  9. Dobbelstein M, and Moll UM (2014) Targeting tumor-supportive cellular machnineries in anticancer drug development.  Nature Reviews Drug Discovery 13(2):179-96.
  10. Alexandrova E, Petrenko O, Nemajerova A, Romano RA,Sinha S and Moll UM (2013). ΔNp63 is required for select routes of reprogramming via multiple mechanisms. Cell Death Diff 20(12):1698-708.

  11. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM (2012). p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 149, 1536-1548. Featured as Cover story of the Cell issue.

  12. Schulz R, Marchenko ND, Holembowski, Dobbelstein M, Moll UM (2012). Inhibiting the HSP90 chaperone destabilizes MIF and thereby inhibits breast tumor progressionJ Exp Med 209(2):275-289.

  13. Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M (2011). Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. PNAS 108(9): 3624-9. Featured in Science, Editor’s Choice vol 331, 18 Febr 2011, page 823. Highlighted in “This Week in PNAS” front section of issue Febr 15, 2011, 108 (7).

  14. Nemajerova A, Petrenko O, Trümper L, Palacios G, Moll UM (2010) Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. J Clin Invest 120(6):2070-80. 

  15. Wolff S, Talos F, Palacios G, Beyer U, Dobbelstein M, Moll UM (2009). The alpha/beta carboxyterminal domains of p63 are required for skin and limb development. Cell Death Diff 16(8): 1108-17. 

  16. Flaminia Talos, Alice Nemajerova, Elsa R. Flores, Oleksi Petrenko and Moll UM (2007). p73 maintains the integrity of the genome and prevents rereplication. Mol Cell 27(4): 647-59.

  17. Marchenko ND, Wolff S, Erster S and Moll UM (2007). Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J 26(4):923-34. 

  18. Nemajerova A, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O (2007). Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J, Feb 21;26(4) 987-97.

  19. Petrenko O and Moll UM (2005).  MIF Interferes with the Rb-E2F Pathway. Mol Cell 17(2): 225-36.

  20. Talos F, Petrenko O, Mena P and Moll UM (2005). Mitochondrially Targeted p53 has Tumor Suppressor Activities In vivo. Cancer Res 65(21):1-11. 

  21. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11(3): 577-90.  

  22. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM (2002). DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is upregulated in human tumors. J Exp Med 196(6): 765-80.